(a) In addition to performing any other duties required by federal law, the board shall:
(1) develop and submit to the commission recommendations for the preferred drug lists the commission adopts under Subchapter E;
(2) suggest to the commission restrictions or clinical edits on prescription drugs;
(3) recommend to the commission educational interventions for Medicaid providers;
(4) review drug utilization across Medicaid; and
(5) perform other duties that may be specified by law and otherwise make recommendations to the commission.
(b) In developing recommendations for the preferred drug lists, the board shall consider the clinical efficacy, safety, and cost-effectiveness of, and any program benefit associated with, a product.

(c) To the extent feasible, the board:
(1) shall review all drug classes included in the preferred drug lists at least once every 12 months; and
(2) may recommend inclusions in and exclusions from the lists to ensure that the lists provide for a range of clinically effective, safe, cost-effective, and medically appropriate drug therapies for the diverse segments of the Medicaid population, children receiving health benefits coverage under the child health plan program, and any other affected individuals.

Text of section effective on April 01, 2025